A collaborative experimental study led by researchers at Cima and Clinica Universidad de Navarra proposes a new therapeutic approach against cancer that dissociates efficacy and toxicity in the use of combined immunotherapy ...
May 3, 2019
0
197
Oncologists at the Fred Hutchinson Cancer Research Center have successfully treated a patient with metastatic melanoma by combining two different types of immunotherapy. Cassian Yee and colleagues describe their approach ...
May 30, 2016
0
25
Androgen receptor (AR) signaling affects response to BRAF/MEK inhibitor therapy in both males and females with melanoma, researchers from The University of Texas MD Anderson Cancer Center showed in a study published today ...
Jun 15, 2022
0
51
Researchers at the Icahn School of Medicine at Mount Sinai have identified an allergy pathway that, when blocked, unleashes antitumor immunity in mouse models of non-small cell lung cancer (NSCLC).
Dec 6, 2023
0
110
The likelihood of a patient responding to immune checkpoint blockade may depend on B cells in the tumor, located within specialized immune-cell clusters known as tertiary lymphoid structures (TLS), according to researchers ...
Jan 15, 2020
0
297
Mount Sinai researchers have developed a way to use immunotherapy drugs against treatment-resistant non-Hodgkin's lymphomas for the first time by combining them with stem cell transplantation, an approach that also dramatically ...
Aug 2, 2019
0
1
A new study led by investigators from Brigham and Women's Hospital in collaboration with colleagues at the Broad Institute examines the effects of checkpoint blockade therapies on different populations of T cells, a key class ...
Jan 8, 2019
0
72
A new study by researchers at The Ohio State University Comprehensive Cancer Center—Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC—James) suggests a way to re-energize critical killer ...
Jan 24, 2023
0
54
New research from a collaborative team at Cleveland Clinic, led by Timothy Chan, MD, Ph.D., Chair of the Center for Immunotherapy and Precision Immuno-Oncology in the Lerner Research Institute, is demonstrating that pathogenic ...
Jul 13, 2022
0
53
A research group led by professor Jesper Ekelund showed that by giving a very large dose of famotidine (200 mg daily), sufficient amounts of the drug are able to penetrate the so-called blood-brain barrier to affect the histamine ...
Jul 1, 2013
0
3
